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The ability to predict patients’ responses to chemoradiotherapy by analyzing pre-treatment biopsy specimens would be
valuable for managing oesophageal squamous-cell cancer. To this end, the expression of p53, thymidine phosphorylase and
vascular endothelial cell growth factor was analyzed by immunohistochemistry in 52 patients with oesophageal squamous-cell
cancer prior to chemoradiotherapy. Treatment consisted of radiotherapy (40 Gy) and 5 day-infusion of 5-Fluorouracil
(500 mg m
72 per day) combined with cisplatin (10 mg m
72 per day). Following treatment, imaging and endoscopic
reassessment was performed to establish treatment response. Thirty-one patients underwent radical surgery and 21 patients
were treated with an additional 20 Gy of radiotherapy. Of the tumours studied, 58% were p53-positive, 40% thymidine
phosphorylase-positive and 44% vascular endothelial cell growth factor-positive. A clinical response was observed in 36
patients (69%) and was negatively associated with thymidine phosphorylase expression (P=0.02) and vascular endothelial cell
growth factor expression (P50.001). However, the 5-year survival rate was signiﬁcantly lower only in patients with vascular
endothelial cell growth factor-positive tumours (P=0.037). Multivariate analysis identiﬁed vascular endothelial cell growth factor
as a signiﬁcant independent prognostic factor (P=0.0147). These results suggest that expression of angiogenic factors has
predictive value for the treatment response and outcome of patients with oesophageal cancer.
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Despite improvements in surgical techniques, rapid fatal recurrence
is common in patients with advanced oesophageal cancer (Isono et
al, 1982, 1990). Because surgical resection alone rarely results in
long-term survival, efforts are now focused on combined multi-
modality treatments in an attempt to improve local control and
eliminate micro-metastasis present at the time of surgery.
Recently, although neo-adjuvant chemoradiotherapy (CRT)
followed by oesophagectomy has become widespread after several
favourable pilot studies were reported (Poplin et al, 1996; Stahl
et al, 1996; Ancona et al, 1997; Ide, 1997), contradictory data have
also been published (Bosset et al, 1997; Tamin et al, 1998). A major
problem in this context seems to be that a lower rate of cancer-
related deaths after combined treatment is counterbalanced by a
higher rate of treatment-associated mortality. Because only patients
with potentially responsive tumours would beneﬁt from such
aggressive treatment, prediction of treatment response by means
of tissue analysis is invaluable in the management of these patients
with advanced oesophageal cancer. If non-responsive tumours
could be identiﬁed, these patients could be spared the signiﬁcant
toxicity, time, and ﬁnancial expense associated with intensive ther-
apeutic regimens. Determination of appropriate pre-treatment
factors necessary for prediction of patients’ responses to CRT is
vital and can be achieved by ‘biological staging’ using predictive
biological factors. Therefore, a primary consideration in setting
up CRT for patients with advanced oesophageal cancer is to iden-
tify markers serving as good predictors for treatment response.
Given the importance of alterations in the p53 gene and expres-
sion of angiogenic factors for progression of oesophageal cancer, it
is reasonable to explore whether such markers may have predictive
value for the patients’ response to therapy. Indeed, genetic altera-
tion of p53 or p53 protein over-expression has already been
reported to be a good predictor for treatment response and survi-
val in oesophageal cancer (Sarbia et al, 1994; Nabeya et al, 1995;
Casson et al, 1998; Ribeiro et al, 1998; Yang et al, 1999; Kobayashi
et al, 1999; Shimada et al, 2000).
Angiogenesis plays an essential role in the process of growth and
metastasis of solid tumours (Weidner, 1995, Hanahan and Folk-
man, 1996). Among several angiogenic factors, vascular
endothelial cell growth factor (VEGF) has been shown to be vital
for pathological angiogenesis. VEGF induction and vascularization
of solid tumours has been shown to play an important role in the
response to chemotherapeutic agents and radiation therapy (Shin-
tani et al, 2000; Veikkola et al, 2000; Volm and Rittgen, 2000).
Immunohistochemical (IHC) analyses of oesophageal carcinoma
have revealed that angiogenesis, as determined by micro-vessel
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www.bjcancer.comdensity, is a prognostic factor (Inoue et al, 1997; Kitadai et al,
1998; Sato et al, 1999; Shih et al, 2000). Over-expression of VEGF
protein is, therefore, at least partially responsible for the malignant
potential in oesophageal cancer and represents a useful prognostic
marker. Thymidine phosphorylase (TP, EC 2.4.2.4), which is iden-
tical to platelet-derived endothelial cell growth factor, is also a
potent angiogenic factor (Grifﬁths and Stratford, 1997). In oeso-
phageal squamous-cell carcinoma (SCC), IHC studies indicated
that high TP expression was associated with angiogenesis, tumour
progression and poor prognosis (Igarashi et al, 1998; Takebayashi
et al, 1999). In head and neck SCC, a low percentage of cancer cells
with nuclear TP expression in pre-treatment biopsies was asso-
ciated with a high rate of complete regression after combined
CRT (Koukourakis et al, 2000). Although angiogenic factors were
reported as prognostic indicators in oesophageal cancer after
surgery, little information is available on their predictive value
for the treatment response and their prognostic signiﬁcance in
patients receiving CRT.
In this report, we analyzed pre-treatment biopsy samples from
52 patients with primary oesophageal SCC by IHC to identify
p53, TP and VEGF expression. We found that TP and VEGF
expression were signiﬁcantly associated with clinical responses to
treatment. We also found that VEGF expression was an indepen-
dent prognostic factor for patients with oesophageal SCC
following CRT.
MATERIALS AND METHODS
Patients and samples
For inclusion in this study, patients were required to have
presented at the Department of Academic Surgery, Chiba Univer-
sity Hospital, between 1991 and 1999 with histologically-proven
primary SCC of the oesophagus and to have been treated by exter-
nal beam radiotherapy concurrent with chemotherapy. A review of
the clinical records identiﬁed 61 patients satisfying entry criteria.
Nine of these were subsequently excluded because of the small size
of the biopsy (ﬁve patients), previous or synchronous malignancies
(two patients) or the existence of distant metastasis at the onset of
treatment (two patients). The other 52 patients with primary
advanced oesophageal squamous cell carcinoma underwent a
prospective, non-randomized trial of combination CRT. The
patients consisted of 43 males (83%) and nine females (17%), with
a mean age of 65+9.6 years. Pre-treatment evaluation included
clinical staging according to the TNM classiﬁcation (Sobin and
Wittekind, 1997), determined by radiography, endoscopic ultra-
sonography and computed tomography examinations (Table 1).
This study was reviewed and approved by the Chiba University
School of Medicine Internal Review Board. Patient eligibility crit-
eria included the following: (i) histologically conﬁrmed SCC of
the cervical and thoracic oesophagus; (ii) age limit of 80 years
and Karnofsky performance status of greater than 70%; (iii) white
blood cell count greater than 4000 cells mm
73, haemoglobin
greater than 10 g, platelet count greater than 100000 mm
73, crea-
tinine less than 1.5 mg dl
71 and creatinine clearance greater than
50 ml min
71, total bilirubin less than 1.5 mg dl
71; and (iv)
informed consent according to the Declaration of Helsinki present.
At least three biopsy samples taken from different areas of the
tumour of these patients for IHC analysis were obtained before
treatment and stored until assay.
Treatment plan
The chemotherapy schedule consisted of cisplatin 10 mg m
72
day
71 intravenous administration and 5-ﬂuorouracil 500 mg
m
72 day
71 in continuous intravenous infusion for 5 days. The
radiotherapy dose of 2 Gy per day was initiated on day 1 of
chemotherapy and continued daily for 5 days per week for 4 weeks,
totalling 40 Gy. The target was the entire oesophagus as well as the
supraclavicular lymph nodes for the upper and mid-third lesions.
Coverage of the celiac lymph nodes was decided according to
computed tomography examination. Of the 52 patients, 21 were
treated with an additional 20 Gy of radiotherapy (to be a deﬁnitive
CRT) and 31 were treated by transthoracic oesophagectomy. Post-
operative treatment was not given. Resection of the oesophagus
and the proximal stomach was performed by a combined right
thoracic abdominal and cervical approach. Resection included exci-
sion of the para-oesophageal, paracardial, left gastric and celiac
lymph nodes.
Deﬁnition of the response to treatment
Re-evaluation of the primary tumour was performed by computed
tomography, endoscopy and gastrography 2 weeks after comple-
tion of CRT. The response to treatment was basically evaluated
according to the General Rules for Esophageal Cancer proposed
by the Japanese Society for Esophageal Disease (1998) and was
categorized as either a complete or partial response, stable or
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Table 1 Relationship between the immunoreactivity of the biopsy specimens and the clinicopathological
factors in 52 patients with oesophageal cell carcinoma
a
Number of patients p53 IHC(+) TP IHC(+) VEGF IHC(+)
Variables (n=52) (n=30) P (n=21) P (n=23) P
Gender Male 43 25 0.699 17 0.533 22 0.03
Female 9 5 4 1
Age 560 21 16 0.025 7 0.242 9 0.549
560 31 14 14 14
Location Upper 9 5 0.585 3 0.467 1 0.03
Lower 43 25 18 22
Tumour size 570 mm 23 7 50.001 8 0.328 6 0.019
570 mm 29 23 13 17
Tumour depth T1–T2 10 8 0.107 3 0.355 4 0.525
T3–T4 42 22 18 19
N factor N(7) 8 4 0.459 3 0.59 3 0.493
N(+) 44 26 18 20
M factor M(7) 30 15 0.152 13 0.414 10 0.059
M(+) 22 15 8 13
aThe P-value was determined using Fisher’s exact probability.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 552–557progressive disease. This evaluation was based on a comparison of
initial and pre-operative imaging studies. A complete response was
deﬁned as the disappearance of all signs and symptoms of the
tumour. A partial response was deﬁned as a reduction of 50%
or more of the tumour volume and microscopic evidence of resi-
dual tumour in postoperative specimens. The sum of the
perpendicular diameter of the lesion was used to calculate tumour
volume. Stable disease was deﬁned as less than a 50% decrease or
less than a 25% increase in tumour volume. Progressive disease
was deﬁned as no signiﬁcant change in tumour mass or more
than a 25% increase in tumour volume. The patients who showed
a response, complete or partial, were categorized as responders.
The remaining patients with either stable or progressive disease,
were categorized as non-responders.
All patients underwent clinical examination and imaging every 3
months for the ﬁrst year after the end of treatment; thereafter,
every 6 months. Thirty-four patients (65%) were followed until
their deaths with a median follow-up period for survivors of 36
months.
Immunohistochemical staining for p53, TP and VEGF
Parafﬁn-embedded tissue blocks of formalin-ﬁxed three biopsy
specimens from different areas of the tumour were processed
for conventional histological assessment by hematoxylin and eosin
(H&E) staining and IHC analysis by the avidin–biotin–peroxi-
dase method (Hsu et al, 1981). p53, TP and VEGF protein
over-expression in the biopsy specimens was detected by anti-
p53 monoclonal antibody (DO-7, DAKO, Carpenteria, CA,
USA), anti-human TP (Nippon Roche Research Center, Kama-
kura, Japan; Nishida et al, 1996) and anti-human VEGF (A-20,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) using
conventional peroxidase methods (Ribeiro et al, 1998). In brief,
4 mm thick sections were deparafﬁnized in xylene, dehydrated
through graded alcohol concentrations and incubated in citrate
buffer (pH=6.0) for 5 min using a household microwave oven
at 800 W. After microwave exposure, the slides were allowed to
cool to room temperature. The slides were brieﬂy washed with
PBS and incubated for 15 min with 3% hydrogen peroxide in
methanol to block endogenous peroxidase activity. The antibodies
to p53, TP and VEGF were diluted 1:250, 1:500 and 1:100,
respectively and incubated for 24 h at 48C. Biotinylated anti-
mouse/rabbit antibody (DAKO) at a dilution of 1:500 was used
as the second antibody. After washing, ABC (DAKO) was applied
and diaminobenzydine was used for visualization.
The stained sections were evaluated at a high magniﬁcation
(6400). Staining was considered positive for p53 when more than
10% of the cells’ nuclei were strongly stained. Staining was consid-
ered positive for TP or VEGF when more than 10% of the tumour
cells were strongly stained. Evaluation of this immunoreactivity of
three biopsy specimens was performed without knowledge of the
patients’ clinicopathological factors by two investigators simulta-
neously (T Hoshino and A Takeda). When more than two of
three biopsy specimens revealed positive immunoreactivity, stain-
ing was considered positive.
Statistical analyses
Fisher’s exact probability test was applied to determine the signiﬁ-
cance of the difference between two groups. Actual 5 year survival
rates were compared between the two groups. Survival probabilities
were calculated by the product limit method of Kaplan and Meier.
Differences between groups were tested using the log-rank test. The
inﬂuence of each clinicopathologic variable on survival was
assessed by Cox’s proportional hazards model. All statistical
analyses were carried out using the Stat View program (SAS Insti-
tute Inc., Cary, NC, USA), and all P values were considered to be
statistically signiﬁcant if 50.05.
RESULTS
Immunoreactivity and clinicopathological variables
p53 expression was detected on the cells’ nuclei. TP expression was
detected on the cell cytoplasms, on the nuclei and on the some
tumour-inﬁltrating stromal cells. VEGF expression was mainly
detected on the cell cytoplasms or the membranes of the carcinoma
cells (Figure 1). The overall frequency of expression of p53, TP and
VEGF, summarized in Table 1, was 58% (30 of 52), 40% (21 of 52)
and 44% (23 of 52), respectively. By p53-IHC, signiﬁcant differ-
ences between positive and negative groups were observed for the
factors age (P=0.025) and tumour size (P50.001). By TP-IHC,
no signiﬁcant differences between the two groups were found. By
VEGF-IHC, signiﬁcant differences between the two groups were
observed in terms of gender (P=0.03) and tumour size (P=0.019).
Response to treatment and prognosis
Overall responses, including complete and partial responses, were
observed in 36 patients (69%), with no response in the remaining
16 (31%). No signiﬁcant differences were observed between the
response rates of p53-ICH-positive or negative tumours (67 vs
73%, P=0.45) (Figure 2). However, the response rate of TP-ICH-
positive tumours was signiﬁcantly lower than TP-ICH-negative
tumours (43 vs 87%, P=0.02). A similar tendency was observed
for VEGF-ICH-positive or negative tumours (43 vs 90%,
P50.001). The overall 5-year survival rate was signiﬁcantly higher
in the responder group than the non-responder group (14.5 vs
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Figure 1 Representative p53, TP and VEGF immunoreactivity. (A) p53-
IHC positive, (B) p53-IHC negative, (C) TP-IHC positive, (D) TP-IHC
negative, (E) VEGF-IHC positive, (F) VEGF-IHC negative.
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Figure 2 Relationship between immunoreactivity of the biopsy speci-
mens and clinical responses to CRT in patients with oesophageal SCC.
The P-values were determined by Fisher’s exact probability testing.
Angiogenic factors and prognosis of oesophageal cancer
H Shimada et al
554
British Journal of Cancer (2002) 86(4), 552–557 ã 2002 Cancer Research UK6.3%, P=0.0178) (Figure 3a). A similar tendency was observed in
each group of the patients having CRT only (Figure 3b) and the
patients having CRT followed by surgery (Figure 3c). However,
because the number of the patients in each group were not enough
to reach statistically signiﬁcant levels (P=0.069 and 0.089, respec-
tively).
Prognostic relevance and multivariate analysis
Using univariate analysis, treatment modality, tumour depth, N
factor and VEGF-IHC status yielded a signiﬁcant estimate of prog-
nosis (Table 2). In contrast, neither p53-IHC status nor TP-IHC
status was informative for the prognosis after CRT in these oeso-
phageal SCC patients. To determine independent prognostic
values for patients’ survival, a Cox’s regression model was
constructed using TNM factors and IHC status (Table 3). VEGF-
IHC was thereby identiﬁed as an independent predictor of patient
survival (P=0.0147; hazards ratio, 2.424; 95% CI, 1.190–4.936).
The other independent prognostic factors were treatment modality
(P=0.0007; hazards ratio, 3.465; 95% CI, 1.688–7.115) and N
factor (P=0.018; hazards ratio, 3.874; 95% CI, 1.261–11.901).
DISCUSSION
In this study, the clinical signiﬁcance of ICH-positivity for p53, TP
and VEGF in pre-treatment biopsy specimens was examined in 52
patients with oesophageal SCC prior to CRT. Our results indicated
that both TP and VEGF but not p53 expression was associated with
treatment response. VEGF expression was also identiﬁed as an
independent prognostic factor.
In contrast to previous reports (Ribeiro et al, 1998; Yang et al,
1999), we found that p53 expression was not a predictive indicator
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Figure 3 Kaplan–Meier survival according to treatment response and
treatment modality. (A) All patients (n=52). (B) The patients having
CRT alone (n=21). (C) The patients having neoadjuvant CRT followed
by surgery (n=31). The P-values were determined using log-rank test.
Table 3 Risk factor affecting survival rate by multivariate Kaplan–Meier
analysis in 52 patients with oesophageal squamous cell carcinoma
Variables Multivariate P Hazards ratio 95.0% CI
CRT vs CRT+Surgery 0.0007 3.465 1.688–7.115
T1–T2 vs T3–T4 0.5474 1.318 0.536–3.240
N(7) vs (+) 0.0180 3.874 1.261–11.901
M(7) vs M(+) 0.3832 3.344 0.693–2.598
p53 (7) vs (+) 0.1126 1.738 0.870–3.743
TP (7) vs (+) 0.3200 1.393 0.722–2.707
VEGF (7) vs (+) 0.0147 2.427 1.190–4.936
Table 2 UnivariateKaplan–Meieranalysisin52patientswithoesophageal
squamous cell carcinoma
a
Number of 5-year
Variables patients survival rate P
Gender Male 43 22.2 0.167
Female 9 7.9
Age 560 21 14.5 0.230
560 31 7.7
CRT+Surgery 31 15.5 50.001
CRT alone 21 0
Location Upper 9 33.3 0.357
Lower 43 4.7
Gross type Type 1,2 26 22.2 0.527
Type 3,4 26 0
Tumour size 570 mm 23 10.4 0.586
570 mm 29 0
Tumour depth T1–T2 10 48.0 0.047
T3–T4 42 5.2
N factor N (7) 8 50.5 0.023
N (+) 44 5.5
M factor M (7) 30 13.0 0.939
M (+) 22 13.0
p53 IHC (7) 22 8.5 0.268
IHC (+) 30 5.8
TP IHC (7) 21 15.5 0.316
IHC (+) 31 9.5
VEGF IHC (+) 23 22.8 0.037
IHC (+) 29 4.4
aThe P-value was determined using Log-rank test.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 552–557of treatment response. We suggest three possible explanations for
p53-IHC status not being associated with either treatment response
or survival. First, p53-ICH-negative cells also include instances of
loss of both p53 alleles or nonsense mutations. Second, there
may be a discrepancy in sequence analysis between assessments
from different locations, i.e. endoscopic biopsy samples and surgi-
cally resected specimens. Endoscopic biopsy samples do not
accurately represent characteristics of all tumour cells. In our other
series, we compared the p53-IHC and TP-IHC staining results
from the biopsy and resected specimens. The sensitivity was more
than 90% and the speciﬁcity was around 80% (unpublished data).
In this present study, because all patients received CRT, we could
not compare the IHC staining results from the biopsy and resected
specimens for the validity of the data. Third, there are signiﬁcant
differences in histology between the tumours examined in the
previous reports and our study, because all of our cases were histo-
logically proven to be SCC, whereas more than two-thirds of the
previously-reported cases were adenocarcinomas. There might well
be differences between the response rates of SCC and adenocarci-
noma even with the same p53 mutations.
The association of angiogenic factor expression with a high inci-
dence of treatment failure may contribute to the resistance to
therapy observed in both the TP-ICH- and VEGF-ICH-positive
groups. The duration to treatment failure and the treatment
response rates were signiﬁcantly poorer in the VEGF-ICH-positive
group compared to the VEGF-IHC-negative group, and thus would
eventually lead to poorer survival, as reported previously (Kitadai
et al, 1998; Sato et al, 1999; Shih et al, 2000). Blocking VEGF activ-
ity was reported to enhance the anti-tumour effects of ionizing
radiation (Gorski et al, 1999). Those authors proposed a model
in which induction of VEGF by ionizing radiation contributes to
the protection of tumour vessels from radiation-mediated cytotoxi-
city. In our present study, both the TP-ICH- and VEGF-ICH-
positive groups experienced signiﬁcantly lower treatment response
rates. Therefore we propose a new model in which VEGF and
TP expression both contribute to the protection of tumour blood
vessels from CRT-mediated cytotoxicity and thereby to treatment
resistance.
One question raised by the present study is why TP expression
was not a signiﬁcant prognostic factor, despite the fact that it was
signiﬁcantly associated with response rate. We suggest two possible
reasons for this result. First, TP expression in our series was not
associated with TNM factors, in contrast to previous reports (Igar-
ashi et al, 1998; Takebayashi et al, 1999). Second, the complete
response rate of TP-ICH-negative patients was relatively low
compared to VEGF-ICH-negative patients. In the multivariate
analysis, because TP expression was signiﬁcantly associated with
VEGF expression (P=0.03, data not shown), consistent with
previous reports (Fujimoto et al, 1998; O’Byrne et al, 2000), VEGF
might be identiﬁed as an independent prognostic factor in place of
TP. As the small number of patients enrolled in this study was a
limitation, further larger scale studies are required to address this
question.
The development of convenient and reliable biomarkers predict-
ing which patients are most likely to develop recurrence of primary
disease would allow intervention strategies to be speciﬁcally
targeted to patients most likely to beneﬁt from them. Such a
capability would be cost-effective and would avoid treating patients
with a low response potential, who do not react to the usual adju-
vant therapy. The present study suggests that patients with
locoregional advanced oesophageal SCC positive for angiogenic
factors are less likely to beneﬁt from neoadjuvant CRT with the
usual regimen than patients who are negative for angiogenic
factors. Among 52 patients, 13 had tumours both TP- and
VEGF-IHC-positive and a further 21 both TP- and VEGF-IHC-
negative. Only three patients in the former group of 13 responded
to therapy whereas 20 patients of the latter group of 21 did
respond (data not shown). Moreover, none of the 13 in the TP-
and VEGF-IHC-positive group survived 45 years. Therefore,
monitoring angiogenic factors may be an important determinant
for the differential application of therapy, not only for primary
tumours but also for adjuvant therapy after deﬁnitive treatment
of oesophageal cancer. It is essential to evaluate the prognosis sepa-
rately in patients having neoadjuvant therapy with resection (n=31)
and neoadjuvant therapy only (n=21) groups to conﬁrm the prog-
nostic value of VEGF-IHC. However, because a limited number of
the patients in each groups, TNM factors and VEGF-IHC were
assessed by multivariate analysis with treatment modality. Although
neither p53-IHC nor TP-IHC were not independent prognostic
factor, both VEGF-IHC and the treatment modality were selected
as independent prognostic factors.
It is very difﬁcult to develop an alternative treatment strategy for
patients with tumours expressing angiogenic factors; however, radi-
cal surgery should at least be conducted without delay in these
cases. VEGF-ICH-positive patients are deemed to have higher risks
for recurrence and thus need more aggressive adjuvant therapy
than the VEGF-ICH-negative group. Anti-VEGF therapy using
anti-VEGF antibodies (Gorski et al, 1999; Lee et al, 2000) or
anti-VEGF receptor therapy (Klement et al, 2000; Geng et al,
2001) may be useful in improving the effect of CRT and the prog-
nosis of such VEGF-positive patients. Inhibitors of TP and
prodrugs that are activated by TP (Ishikawa et al, 1998; Miwa et
al, 1998; Takebayashi et al, 1999) may suppress the growth of
TP-expressing tumours and may enhance the effect of CRT for
patients with oesophageal SCC.
In conclusion, the present study indicates that monitoring the
expression of angiogenic factors in biopsy specimens from patients
with oesophageal SCC prior to treatment may have predictive value
for their response to CRT and hence overall prognosis.
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